Related references
Note: Only part of the references are listed.COVID-19 and the cardiovascular system
Ying-Ying Zheng et al.
NATURE REVIEWS CARDIOLOGY (2020)
Interaction between RAAS inhibitors and ACE2 in the context of COVID-19
Jean-Jacques Mourad et al.
NATURE REVIEWS CARDIOLOGY (2020)
The renin-angiotensin-aldosterone system and its therapeutic targets
Katrina M. Mirabito Colafella et al.
EXPERIMENTAL EYE RESEARCH (2019)
The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Thiago Ruiz Rodrigues Prestes et al.
CURRENT DRUG TARGETS (2017)
ANGIOTENSIN-CONVERTING ENZYME INHIBITION ATTENUATES LIPOPOLYSACCHARIDE-INDUCED LUNG INJURY BY REGULATING THE BALANCE BETWEEN ANGIOTENSIN-CONVERTING ENZYME AND ANGIOTENSIN-CONVERTING ENZYME 2 AND INHIBITING MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATION
Yingchuan Li et al.
SHOCK (2015)
Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist
Roelie M. Woesten-van Asperen et al.
JOURNAL OF PATHOLOGY (2011)
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2
CM Ferrario et al.
CIRCULATION (2005)
Share Paper
